| News
Investment activity begins to pick
up
Sunday Business Post,
March 7th 2010
“Origin, along
with a number of private Irish equity investors, has just completed
the acquisition of a UK provider of clinical software solutions
for the healthcare sector”. Synbiotix Ltd provides Hospital information
systems, clinical systems and clinical audit tools to a number
of UK Hospital Trusts.
Working in corporate finance
has been a difficult task over the last year. Overall activity
is down, and there were no guarantees that any deals which had
been in place would make it through to completion. But
the outlook for 2010 is better and many players in the sector
are far more optimistic about the levels of mergers and acquisitions
(M&A) activity.
"Corporate finance activity for Origin
has started to pick up since last summer, particularly in the
technology, health and professional services sectors," said Dermot
Grant, managing
director of Origin Corporate Finance which specialises
in mergers and acquisitions, business sales and investment.
According
to Grant, the major focus at Origin is currently on investment
work in the software and technology sector although it has also
been active on transactions in the professional services sector. But
there is also a significant amount of work in assisting companies
across all sectors in re-organising and restructuring shareholding,
the provision of exit advice to shareholders, management buy ins
and incentive schemes for management.
"This area is vital for all
companies to consider in this post-boom era,” he said. “Share
ownership, capital and debt structures, which were appropriate
in the good times, are likely to need an overhaul in these tougher
times."
These greater levels of investment activity
are in marked contrast to the early part of 2009 when, according
to Grant, things were very difficult, with time mainly being
spent on rescue and re-organisation work.
“While there were active
deals, it was extremely difficult to get them across the line
- with the perception that values continued to drop sharply during
the sales process, with the absence of finance from banks and
with conservative private investors,” he said. "While
in the past, you could rely on part of the deal to be leveraged
with bank debt, last year this was substantially replaced by an
absolute dependency on private equity or finance from a trade buyer."
Although
the perception is that there is great opportunity for well-capitalised
buyers, in acting for acquisitive trade purchasers, Origin has
found that when targeting potential acquirers there is a tendency
for potential targets to rebuff an approach and insist on holding
on until things improve.
That is, of course, unless they have no other choice but to sell,
or are in a sector where values remain reasonable.
"Going forward,
we are hopeful there will be plenty of work in all sectors and
there is a significant amount of private equity available to close
deals," says Grant.
"A large part of private equity is coming
from individuals, rather that private equity houses. We
consider that banks will re-engage to provide loan capital, albeit
with more stringent and costly conditions. Bank of Ireland recently
announced the provision of acquisition and working capital facilities
for an acquisition of a company in the healthcare sector," he
said. "This would indicate a willingness from banks to provide
support either directly or indirectly through venture capital
funds."
"Banks are providing support along with
Enterprise Ireland and large corporates to a number of venture
capital funds - for example, NCB Ventures backed by Ulster Bank
and Kernel Capital, backed by Bank of Ireland. Hopefully
the focus on direct bank support in the future will be more favourably
balanced in favour of enterprise, rather than property related
activities".
Still,
Origin envisaged that management buyout activity will remain
quiet, particularly with the lack of leverage. But deals are
being done with the help of private equity, strategic investors
and imaginative deferred consideration mechanisms where there
is a determination for the seller to exit.
"We consider that attitude to valuation
will be significantly more conservative," said Grant. "Even
in software, EBITDA multiples will be the norm over turnover multiples.
Intellectual property valuations will be subject to stringent lifecycle
and competitor product review. But we are hopeful that the worst
is over, and the supply of capital will continue to improve."
|